Qube Research & Technologies LTD Halozyme Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

$91.4 Billion
Q3 2025

A detailed history of Qube Research & Technologies LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 601,276 shares of HALO stock, worth $42.1 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

601,276

Previous 986,069 39.02%

Holding current value

$42.1 Million

Previous $51.3 Million 14.03%

% of portfolio

0.05%

Previous 0.05%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$52.92 - $78.28 $20.4 Million - $30.1 Million	-384,793 Reduced 39.02%	601,276 $44.1 Million
Q2 2025 Aug 14, 2025	BUY	$47.91 - $70.14 $47.2 Million - $69.2 Million	986,069 New	986,069 $51.3 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $751,105 - $1.08 Million	17,644 Added 7.74%	245,750 $11.7 Million
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $9.61 Million - $12.1 Million	187,234 Added 458.1%	228,106 $13 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $12.2 Million - $16.9 Million	-322,467 Reduced 88.75%	40,872 $2.14 Million

Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $3.64 Million - $4.53 Million	108,026 Added 42.31%	363,339 $14.8 Million
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $7.65 Million - $9.66 Million	229,532 Added 890.31%	255,313 $9.44 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $4.1 Million - $4.96 Million	-112,574 Reduced 81.37%	25,781 $984,000
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $3.61 Million - $4.62 Million	119,311 Added 626.5%	138,355 $4.99 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $2.82 Million - $4.77 Million	-85,672 Reduced 81.81%	19,044 $727,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $4.19 Million - $6.22 Million	104,716 New	104,716 $5.96 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $1.99 Million - $2.58 Million	53,329 New	53,329 $2.35 Million
Q4 2021 Feb 01, 2022	SELL	$31.82 - $40.75 $323,068 - $413,734	-10,153 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$38.47 - $46.42 $445,444 - $537,497	-11,579 Reduced 53.28%	10,153 $413,000
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $1.1 Million - $1.45 Million	-28,322 Reduced 56.58%	21,732 $987,000
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $451,915 - $588,485	-11,438 Reduced 18.6%	50,054 $2.09 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $1.27 Million - $2.15 Million	49,219 Added 401.03%	61,492 $2.63 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $124,530 - $143,349	-4,838 Reduced 28.27%	12,273 $323,000
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $278,053 - $458,745	17,111 New	17,111 $459,000
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $1.03 Million - $1.61 Million	-73,897 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $1.1 Million - $1.44 Million	73,897 New	73,897 $1.31 Million

Others Institutions Holding HALO

# of Institutions

664

Shares Held

128M

Call Options Held

599K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Halozyme Therapeutics, Inc. Transaction History